Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b lenvatinib plus nivolumab in hepatocellular carcinoma
jRCT2080223794Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenvatinib and nivolumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Safety and tolerability of lenvatinib plus nivolumab. Started Feb 2018; status: completed.
02
Drugs
lenvatinibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080223794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223794.